An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice

Roche

Status: Completed

Conditions: Anemia

Study type: Observational

Funder types: Industry

Identifiers

NCT01690455

ML25701

Details and patient eligibility

About

This observational, multi-center study will evaluate the efficacy and safety of Mircera (methoxy polyethylene glycol-epoetin beta) in renal anemia correction in dialysed patients in daily clinical practice. Patient will receive Mircera according to local summary of product characteristics. Data will be collected for 12 months.

Enrollment: 247 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients, >/=18 years of age
• Adequate iron status
• Signed informed consent form

Exclusion criteria

• Anemia due to non-renal causes
• Where investigator considers the patient unsuitable for inclusing for other reasons (e.g. severe co-morbidities as active bleeding, infections or cancer)
• Pregnant or lactating female patients
• Any contraindications against treatment with Mircera (according to local Summary of Product Characteristics)

Trial design

247 participants in 1 patient group

Cohort